Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
 
No Matching Results
Advanced search
or
Market: Market:

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Thinking about buying stock in Aurora Cannabis Inc., Akari Therapeutics, Atossa Genetics Inc., Boeing Co., or Reebonz Holding Ltd.? PR Newswire - Wed Apr 24, 8:31AM CDT
CMTX - Wed Apr 24, 8:31AM CDT

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ.

AKTX : 2.41 (-4.74%)
ACBFF : 8.6900 (-12.80%)
ATOS : 2.78 (+1.65%)
BA : 352.78 (-1.66%)
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights GlobeNewswire - Tue Apr 23, 3:01PM CDT
CMTX - Tue Apr 23, 3:01PM CDT

-- Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) expected to start Q4 2019

AKTX : 2.41 (-4.74%)
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid GlobeNewswire - Tue Apr 23, 7:30AM CDT
CMTX - Tue Apr 23, 7:30AM CDT

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 2.41 (-4.74%)
Recent Analysis Shows Extra Space Storage, OPKO Health, El Pollo Loco, Willis Towers Watson Public, Molina Healthcare, and Akari Therapeutics Market Influences -- Renewed Outlook, Key Drivers of Growth GlobeNewswire - Mon Apr 15, 7:30AM CDT
CMTX - Mon Apr 15, 7:30AM CDT

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Extra Space Storage Inc (NYSE:EXR),...

WLTW : 180.02 (+0.96%)
AKTX : 2.41 (-4.74%)
MOH : 133.88 (-0.39%)
OPK : 1.98 (-5.71%)
LOCO : 11.10 (-1.25%)
EXR : 106.25 (-0.24%)
Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire - Wed Mar 27, 3:14PM CDT
CMTX - Wed Mar 27, 3:14PM CDT

-- Interim data expected from Akari's Phase I/II clinical trial in atopic keratoconjunctivitis (AKC), a surface of the eye inflammatory disease

AKTX : 2.41 (-4.74%)
Thinking about buying stock in Akari Therapeutics, Presbia Plc, Roku Inc., Snap Inc., or Pareteum Corp.? PR Newswire - Thu Mar 14, 8:31AM CDT
CMTX - Thu Mar 14, 8:31AM CDT

InvestorsObserver issues critical PriceWatch Alerts for AKTX, LENS, ROKU, SNAP, and TEUM.

AKTX : 2.41 (-4.74%)
ROKU : 88.02 (+0.45%)
SNAP : 11.31 (-1.99%)
LENS : 0.32 (-3.03%)
TEUM : 4.84 (-1.43%)
Advancing Clinical Trials for Leukemia Patients is Helping Improve Survival Rate PR Newswire - Thu Mar 14, 7:30AM CDT
CMTX - Thu Mar 14, 7:30AM CDT

According to the Leukemia & Lymphoma Society, the world's largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are...

AKTX : 2.41 (-4.74%)
CELG : 96.36 (+0.11%)
LLY : 117.98 (+1.20%)
GERN : 1.53 (-4.38%)
CELGZ : 0.72 (+2.86%)
MBRX : 1.15 (unch)
Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics's Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire - Wed Mar 13, 7:29AM CDT
CMTX - Wed Mar 13, 7:29AM CDT

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 2.41 (-4.74%)
Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics -- New Research Emphasizes Economic Growth GlobeNewswire - Thu Feb 21, 7:29AM CST
CMTX - Thu Feb 21, 7:29AM CST

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of EnLink Midstream, LLC (NYSE:ENLC),...

ENLC : 11.44 (-0.52%)
AKTX : 2.41 (-4.74%)
ANET : 253.14 (+0.08%)
MHLD : 0.60 (-5.41%)
PEP : 130.07 (+0.79%)
GLIBA : 59.81 (+0.10%)
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks Equity Research - Zacks Investment Research - Mon Feb 4, 11:45AM CST
Zacks Equity Research - ZACKS - Mon Feb 4, 11:45AM CST

Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

AKTX : 2.41 (-4.74%)
ACHN : 2.80 (-2.44%)
HALO : 15.42 (-1.22%)
ALXN : 127.55 (-0.97%)
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks Equity Research - Zacks Investment Research - Tue Jan 29, 10:10AM CST
Zacks Equity Research - ZACKS - Tue Jan 29, 10:10AM CST

Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.

AKTX : 2.41 (-4.74%)
ACHN : 2.80 (-2.44%)
HALO : 15.42 (-1.22%)
ALXN : 127.55 (-0.97%)

Van Meerten Stock Picks

Aaon - Pick of the Day
My Stock Pick of the Day is the HVAC company AAON (AAON).
Tue Apr 23, 12:42PM CDT
AAON -1.55
See More
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot